ArticleBrain imaging and behavior2026
Neuromelanin-sensitive MRI for identifying dopamine transporter imaging abnormality risk in idiopathic rapid eye movement sleep behavior disorder.
Article in Brain imaging and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuromelanin-sensitive magnetic resonance imaging (NM-MRI) enables non-invasive assessment of the substantia nigra pars compacta (SNpc). However, its utility in identifying dopaminergic dysfunction in idiopathic rapid eye movement sleep behavior disorder (iRBD) remains unclear. This study evaluated NM-MRI alterations in the SNpc, stratified by dopamine transporter (DaT) imaging status, to assess its performance in detecting early dopaminergic alterations. This combined retrospective and prospective study included 66 patients with iRBD (45 males, 67.0 ± 6.3 years) and 30 healthy controls (HCs) (11 males, 63.6 ± 6.5 years). Patients with iRBD were divided based on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.